Literature DB >> 10632123

Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer.

D G Bostwick1, C S Foster.   

Abstract

Many clinically important predictive factors in prostate cancer are derived from light microscopic examination of tissue specimens by the pathologist. Two separate international consensus conferences held in 1999 addressed the contemporary status of such prognostic factors, sponsored by the College of American Pathologists (CAP) and the World Health Organization (WHO). Both conferences concluded that the following factors are recommended for routine use based on evidence from multiple published trials: TNM stage, histological grade using the Gleason system, surgical margin status, and serum prostate-specific antigen concentration. The WHO conference additionally recommended use of WHO nuclear grade, location of cancer within the prostate, and pathological effects of treatment. Other factors were categorized as promising or of unproven utility, including a wide variety of histopathologic and genetic markers. Standards are needed for analysis and quantitation of methods of tissue analysis, particularly for immunohistochemical studies and genotypic studies. This report describes the recommendations and conclusions of these two conferences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632123

Source DB:  PubMed          Journal:  Semin Urol Oncol        ISSN: 1081-0943


  14 in total

1.  Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Authors:  Lian-Ming Wu; Zi-Zhou Zhao; Xiao-Xi Chen; Qing Lu; Shi-Teng Suo; Qiang Liu; Jiani Hu; E Mark Haccke; Jian-Rong Xu
Journal:  Br J Radiol       Date:  2016-04-19       Impact factor: 3.039

2.  Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI.

Authors:  Kyung Won Doo; Deuk Jae Sung; Beom Jin Park; Min Ju Kim; Sung Bum Cho; Yu Whan Oh; Young Hwii Ko; Kyung Sook Yang
Journal:  Eur Radiol       Date:  2012-04-01       Impact factor: 5.315

3.  Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study.

Authors:  Daniel Wittschieber; Jens Köllermann; Thorsten Schlomm; Guido Sauter; Andreas Erbersdobler
Journal:  Pathol Oncol Res       Date:  2010-04-23       Impact factor: 3.201

4.  Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.

Authors:  Matthias D Hofer; Alice Fecko; Ronglai Shen; Sunita R Setlur; Kenneth G Pienta; Scott A Tomlins; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

5.  Dysregulation of the annexin family protein family is associated with prostate cancer progression.

Authors:  Wei Xin; Daniel R Rhodes; Collette Ingold; Arul M Chinnaiyan; Mark A Rubin
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

6.  Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia.

Authors:  Vanja Filipovski; Katerina Kubelka-Sabit; Dzengis Jasar; Vesna Janevska
Journal:  Open Access Maced J Med Sci       Date:  2017-08-05

7.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Authors:  Sanaz Memarzadeh; Li Xin; David J Mulholland; Alka Mansukhani; Hong Wu; Michael A Teitell; Owen N Witte
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

8.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Authors:  G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

9.  Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy.

Authors:  Pranav Sharma; Kamran Zargar-Shoshtari; Philippe E Spiess; Wade J Sexton; Michael A Poch
Journal:  Urol Ann       Date:  2016 Apr-Jun

10.  Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature.

Authors:  Hiroaki Kunogi; Yoshiaki Wakumoto; Nanae Yamaguchi; Shigeo Horie; Keisuke Sasai
Journal:  J Contemp Brachytherapy       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.